FSHD

Deals and Financing

Altay Raises $37 Million for Oral DUX4 Program

Altay Therapeutics closed a $37 million Series A co-led by Sound Bioventures and HealthCap to advance DX5057, an oral small-molecule DUX4 inhibitor, through Phase 1 and Phase 2 proof of concept in facioscapulohumeral muscular…

admin
October 14, 2026

Deals and Financing

Soufflé Raises $135 Million for Extrahepatic RNA Delivery

Soufflé Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group. The company plans to fund three lead programs spanning facioscapulohumeral muscular dystrophy, heart failure, and an undisclosed muscle and metabolic target,…

admin
October 13, 2026

Altay Raises $37 Million for Oral DUX4 Program

Soufflé Raises $135 Million for Extrahepatic RNA Delivery

Saturday Rounds